These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21446974)

  • 21. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.
    Höcker B; Tönshoff B
    Paediatr Drugs; 2009; 11(6):381-96. PubMed ID: 19877724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
    Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G
    Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients.
    Baczkowska T; Durlik M
    Pol Arch Med Wewn; 2009 May; 119(5):318-25. PubMed ID: 19579814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.
    de Mattos AM; Olyaei AJ; Bennett WM
    Am J Kidney Dis; 2000 Feb; 35(2):333-46. PubMed ID: 10676738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of calcineurin inhibitors on graft survival.
    Rush D
    Transplant Rev (Orlando); 2013 Jul; 27(3):93-5. PubMed ID: 23743217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
    Höcker B; Feneberg R; Köpf S; Weber LT; Waldherr R; Wühl E; Tönshoff B
    Pediatr Transplant; 2006 Aug; 10(5):593-601. PubMed ID: 16856996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis.
    Xia T; Zhu S; Wen Y; Gao S; Li M; Tao X; Zhang F; Chen W
    Drug Des Devel Ther; 2018; 12():417-428. PubMed ID: 29535503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.
    Tredger JM; Brown NW; Dhawan A
    Drugs; 2008; 68(10):1385-414. PubMed ID: 18578558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion to Everolimus in Kidney Transplant Recipients With Calcineurin Inhibitor-Induced Nephropathy: 3 Case Reports.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
    Transplant Proc; 2019 Jun; 51(5):1424-1427. PubMed ID: 31060742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent.
    Cotterell AH; Fisher RA; King AL; Gehr TW; Dawson S; Sterling RK; Stravitz RT; Luketic VA; Sanyal AJ; Shiffman ML; Posner MP
    Clin Transplant; 2002; 16 Suppl 7():49-51. PubMed ID: 12372044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P; Rostaing L
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney donor age of 50 years or above is a risk factor for calcineurin inhibitor-induced nephrotoxicity.
    Takada Y; Tanabe T; Sasaki H; Tsujimoto T; Hotta K; Okada K; Shiono Y; Minami K; Tanaka H; Harada H
    Clin Transplant; 2024 Jan; 38(1):e15196. PubMed ID: 37975424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.
    Nankivell BJ; Borrows RJ; Fung CL; O'Connell PJ; Chapman JR; Allen RD
    Transplantation; 2004 Aug; 78(4):557-65. PubMed ID: 15446315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments.
    Giessing M; Fuller TF; Tuellmann M; Slowinski T; Budde K; Liefeldt L
    World J Urol; 2007 Jun; 25(3):325-32. PubMed ID: 17333201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcineurin Inhibitors Nephrotoxicity Prevention Strategies With Stress on Belatacept-Based Rescue Immunotherapy: A Review of the Current Evidence.
    El Hennawy HM; Faifi ASA; El Nazer W; Mahedy A; Kamal A; Al Faifi IS; Abdulmalik H; Safar O; Zaitoun MF; Fahmy AE
    Transplant Proc; 2021 Jun; 53(5):1532-1540. PubMed ID: 34020797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
    Campistol JM; Grinyó JM
    Transplantation; 2001 Jun; 71(11 Suppl):SS42-51. PubMed ID: 11583488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity.
    Haas M; Meehan SM; Josephson MA; Wit EJ; Woodle ES; Thistlethwaite JR
    Am J Kidney Dis; 1999 Jul; 34(1):69-84. PubMed ID: 10401019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.